Galderma Targets Amneal’s Generic Rosacea Treatment

Law360, New York (November 10, 2011, 1:35 PM EST) -- Galderma Laboratories Inc. and Supernus Pharmaceuticals Inc. hit generic-drug maker Amneal Pharmaceuticals LLC with a patent infringement suit Tuesday in Delaware challenging Amneal’s bid to market its own version of the rosacea treatment Oracea.

The lawsuit claims that Amneal's recent filing of an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to produce a generic version of 40 mg doxycycline delayed-release capsules infringes three patents, one held by Supernus and two held by Galderma.

The plaintiffs are seeking a ruling that...
To view the full article, register now.